These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 14757293)

  • 1. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.
    Kerenyi Z; Samer H; James R; Yan Y; Stewart M
    Diabetes Res Clin Pract; 2004 Mar; 63(3):213-23. PubMed ID: 14757293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
    Hanefeld M; Patwardhan R; Jones NP;
    Nutr Metab Cardiovasc Dis; 2007 Jan; 17(1):13-23. PubMed ID: 17174222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
    Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
    Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
    Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.
    Rosenstock J; Chou HS; Matthaei S; Seidel DK; Hamann A
    Diabetes Obes Metab; 2008 Sep; 10(10):862-73. PubMed ID: 18201206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Garber A; Klein E; Bruce S; Sankoh S; Mohideen P
    Diabetes Obes Metab; 2006 Mar; 8(2):156-63. PubMed ID: 16448519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
    Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
    Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
    Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
    Rosenstock J; Goldstein BJ; Vinik AI; O'neill MC; Porter LE; Heise MA; Kravitz B; Dirani RG; Freed MI;
    Diabetes Obes Metab; 2006 Jan; 8(1):49-57. PubMed ID: 16367882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
    Seino Y; Rasmussen MF; Nishida T; Kaku K
    Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J; Anderson RJ; Rappaport EB
    Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes.
    Scott R; Loeys T; Davies MJ; Engel SS;
    Diabetes Obes Metab; 2008 Sep; 10(10):959-69. PubMed ID: 18201203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
    Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
    Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
    Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
    Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.
    Comaschi M; Demicheli A; Di Pietro C; Bellatreccia A; Mariz S;
    Diabetes Technol Ther; 2007 Aug; 9(4):387-98. PubMed ID: 17705695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.